DESTINY-Breast03 Phase 3 Study Results
Demographics and Baseline Clinical Characteristics
DESTINY-Breast03
Baseline Characteristics
Age, median (range), years
Region, n (%)
Asia
North America
149 (57.1)
17 (6.5)
54 (20.7)
T-DXd
n = 261
54.3 (27.9-83.1)
T-DM1
n = 263
54.2 (20.2-83.0)
160 (60.8)
17 (6.5)
50 (19.0)
Europe
41 (15.7)
36 (13.7)
Rest of World
Hormone-receptor status, n (%)
131 (50.2)
134 (51.0)
Positive
130 (49.8)
129 (49.0)
HER2 status,a n (%)
Negative
3+
2+ with HER2 ISH+
1+
Visceral disease, n (%)
Yes | No
Prior treatment for mBC, n (%)
234 (89.7)
232 (88.2)
25 (9.6)
30 (11.4)
0
1 (0.4)
184 (70.5) 77 (29.5)
185 (70.3) 78 (29.7)
Pertuzumab
Prior lines of therapy for metastatic disease, n (%)
0-1
2+
HER2, human epidermal growth factor receptor 2; ISH, in situ hybridization; mBC, metastatic breast cancer; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan.
aHER2 status was evaluated by immunohistochemical analysis at a central laboratory. HER2 ISH-positive refers to positive results on in situ hybridization. HER2 status could not be evaluated for 1 patient in each
treatment group. Excluding hormone therapy. "Patients who had had rapid progression (i.e., progression that had occurred within 6 months after receipt of neoadjuvant or adjuvant therapy or within 12 months after
receipt of a neoadjuvant or adjuvant pertuzumab-containing regimen) were considered to have had one line of previous therapy. Lines of previous therapy did not include endocrine therapy.
1. Cortés J et al. N Engl J Med. 2022:386:1143-1154.
240 (92.0)
162 (62.1)
132 (50.6)
129 (49.4)
234 (89.0)
158 (60.1)
126 (47.9)
137 (52.1)
ESMO BC 2022 #1630 Oral
From New England Journal of Medicine, Cortés J et al, Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer, Vol. 386, Pages 1143-1154.
Copyright © 2022 Massachusetts Medical Society. Reprinted with permission [pending] from Massachusetts Medical Society.
38
Daiichi-Sankyo
10View entire presentation